BACE1 and Alzheimer disease: While serum BACE1 activity is also higher in mild to moderate AD patients than age-matched cognitively unimpaired controls, there is no difference between diabetic versus nondiabetic individuals in the symptomatic phase (Cervellati et al., 2020).